Suppr超能文献

[肺移植]

[Lung transplantation].

作者信息

Tamm M, Bolliger C, Solèr M, Perruchoud A P

机构信息

Departement of Innere Medizin, Universitätsklinik Basel.

出版信息

Schweiz Med Wochenschr. 1995 Jun 3;125(22):1092-102.

PMID:7784872
Abstract

Human lung transplantation was successfully performed in the early eighties and is now an option for patients with endstage lung disease, which is associated with poor survival. Most frequent indications for lung transplantation are emphysema, cystic fibrosis, fibrosing alveolitis, primary pulmonary hypertension and Eisenmenger's syndrome. Single lung transplantation (SLT) is most often performed in emphysema, fibrosing alveolitis and other diseases which are not associated with chronic infection of the lung. Double lung transplantation was recently replaced by the technique of sequential single lung or bilateral lung transplantation (BLT). Cardiopulmonary bypass can often be avoided and problems of the airway anastomosis are less frequent using BLT. Main indications for this procedure are cystic fibrosis, bronchiectasis and primary pulmonary hypertension (PPH). In PPH often only SLT is performed. Cor pulmonale is reversible following SLT or BLT even if the heart is not replaced. Combined heart-lung transplantation (HLT) is reserved for some cases of Eisenmenger's syndrome and few centers still prefer HLT in patients with cystic fibrosis. Patients are usually accepted for transplantation when they are considered to have life expectancy of 12 to 24 months. Quality of life and physical working capacity are severely decreased and patients suffer dyspnea NYHA grade III or IV. Most of the patients are hypoxic and need continuous oxygen therapy. Hypercapnia is also a negative predictive factor for survival without transplantation. In PPH cardiac index of less than 2 litres/m2 is associated with poor outcome. Not only absolute values for FEV1 and pO2 have to be considered in finding the best moment for assessment for transplantation but the clinical course of the disease during previous months and years also has to be taken into account. Contraindications to transplantation include acute infection, concomitant diseases of other organs, bronchial carcinoma and psychiatric disorders if noncompliance is likely. To achieve good results after lung transplantation, proper donor and recipient selection, experienced surgery and careful postoperative management are essential. Complications must be diagnosed early to provide effective treatment. Most complications occur within the first months after surgery. Early complications include primary organ failure, pleural bleeding, problems at the site of the airway anastomosis, infection and acute rejection. Acute rejection is common but can be treated successfully if diagnosed early.(ABSTRACT TRUNCATED AT 400 WORDS)

摘要

人类肺移植于20世纪80年代初首次成功实施,如今已成为终末期肺病患者的一种治疗选择,这类患者的生存率较低。肺移植最常见的适应证是肺气肿、囊性纤维化、肺纤维化、原发性肺动脉高压和艾森曼格综合征。单肺移植(SLT)最常用于肺气肿、肺纤维化和其他与肺部慢性感染无关的疾病。双肺移植最近已被序贯单肺或双侧肺移植(BLT)技术所取代。采用BLT通常可以避免体外循环,气道吻合问题也较少见。该手术的主要适应证是囊性纤维化、支气管扩张和原发性肺动脉高压(PPH)。在PPH患者中,通常仅进行SLT。即使不更换心脏,肺心病在接受SLT或BLT后也可逆转。心肺联合移植(HLT)仅适用于某些艾森曼格综合征病例,少数中心仍倾向于对囊性纤维化患者进行HLT。当患者被认为预期寿命为12至24个月时,通常会被接受进行移植。患者的生活质量和体力工作能力严重下降,呼吸困难达纽约心脏协会(NYHA)III级或IV级。大多数患者存在低氧血症,需要持续吸氧治疗。高碳酸血症也是未进行移植时生存的负面预测因素。在PPH患者中,心脏指数低于2升/平方米与预后不良相关。在确定最佳移植评估时机时,不仅要考虑FEV1和pO2的绝对值,还必须考虑疾病在前几个月和几年中的临床病程。移植的禁忌证包括急性感染、其他器官的合并症、支气管癌以及可能不配合治疗的精神障碍。为了在肺移植后取得良好效果,正确选择供体和受体、经验丰富的手术操作以及精心的术后管理至关重要必须早期诊断并发症以便进行有效治疗。大多数并发症发生在术后的头几个月内。早期并发症包括原发性器官衰竭、胸腔出血、气道吻合部位问题、感染和急性排斥反应。急性排斥反应很常见,但如果早期诊断,可以成功治疗。(摘要截取自400字)

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验